3 Forbes Road
United States - Map
Agenus Inc., an immunotherapy company, engages in discovering and developing innovative treatments for patients with cancer and other diseases. Its treatments focus on providing therapeutic benefit through modulation of immune function. The company offers Retrocyte Display, a platform that screens and generates therapeutic antibody drug candidates focused on advancing checkpoint modulators using a high-throughput approach incorporating human antibody libraries expressed in mammalian B-lymphocytes. It is also developing heat shock protein vaccine, which is in Phase II studies for treating cancer and infectious diseases; and QS-21 Stimulon, a saponin-based vaccine adjuvant for use in pre-clinical and clinical stage vaccine programs that target prophylactic or therapeutic impact in a range of infectious diseases and cancer. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
|Agenus Inc.’s ISS Governance QuickScore as of Jul 1, 2015 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 8.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Garo H. Armen Ph.D.,
Founder, Exec. Chairman, Chief Exec. Officer and Chairman of Bus. & Devel. Advisory Committee
|Ms. Christine M. Klaskin ,
Principal Accounting Officer and VP of Fin.
|Dr. Robert B. Stein M.D., Ph.D.,
Chief Scientific Officer
|Ms. Karen Higgins Valentine J.D.,
Chief Compliance Officer, Chief Legal Officer and Sec.
|Mr. Ozer Baysal ,
Chief Bus. Officer
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|